Premier Hospital & Surgical Saver

AIA Premier Hospital & Surgical Saver is the co-payment sister of AIA Premier Hospital & Surgical Extra (PHSE). Same five plans, same annual limits, same geographic ladder, same Personal Medical Management hook — with one structural difference that runs through the entire product:

The customer shares 20% of every approved treatment cost, capped at IDR 4M per treatment in Indonesia/Asia or IDR 25M per treatment in Singapore / Japan / Hong Kong / Worldwide.

In return, the cost of insurance deducted from the base unit-linked policy’s investment account is lower than PHSE’s. The “Saver” in the name is literal — customer saves on premium load by accepting skin in the game.

This is not a coincidental design. POJK 36/2025 (the new conduct-of-business regulation for health insurance) requires a co-payment minimum on most Indonesian health products issued from January 2026 onwards. PHSS is AIA’s POJK-aligned answer; PHSE is the legacy 100%-reimbursement product that will progressively become unavailable for new business. From 2026 onwards, the entire Indonesian health-insurance market starts to look more like PHSS than PHSE.

In one line: Pay less into your unit-linked policy each month; share 20% of any hospital bill up to a fixed cap; receive up to IDR 70 billion lifetime limit with worldwide access if you pick the top plan.

---

The brochure walks through “Bima, 40 years old, Co-Classic plan, diagnosed with liver cancer in policy year 3.”

Critical insight for the agent narrative: the headline “20% co-payment” sounds frightening to a customer who hears “I pay 20% of a Rp 500 million cancer bill.” The cap changes the math materially. On a Rp 110 million hospital episode in Indonesia, customer pays Rp 4 million — under 4%. The pitch is “20% with a hard ceiling,” not “20% of everything.” Agents who quote the percentage without the cap mis-sell the product (in either direction — making it sound either worse or better than it is).

Cap behaviour on overseas treatment: the IDR 25M cap on SG/JP/HK/Worldwide treatment is meaningfully larger. A SGD 80,000 inpatient stay in Singapore would hit the IDR 25M cap, which is roughly SGD 2,200 — closer to a true 3-4% share. Still cheap, but customer’s out-of-pocket scales when they travel for treatment.

---

AIA’s PHSS sweet spot — when a competitor’s prospect is genuinely well-fit for PHSS

• Age 30–55, already holding or willing to hold an AIA unit-linked base policy
• Household income IDR 25M+/month (mass affluent and above) — Co-Classic premium is reasonable; Co-Prestige and Co-Ultimate need IDR 50M+/month to be sensible
• Wants comprehensive hospital cover with lower monthly cost than 100%-reimbursement equivalents
• Comfortable with the concept of co-payment — typically because they have prior international medical experience, employer group medical that already had deductibles, or simply understand that “no co-pay” was always priced into the premium
• Has cash buffer of at least IDR 25M readily accessible (= one worldwide cap)
• Family Plan use case: spouse + up to 3 dependents under one rider with 5% premium discount per added insured

Borderline fit — PHSS may not be the right answer

• Customers who specifically want predictable monthly cost certainty with zero claim exposure — the cap helps, but they will be unhappy at every claim
• Customers travelling frequently to USA — Co-Ultimate is the only plan with US cover, and even there the 100% reimbursement isn’t there for lower plans
• Customers without an existing AIA unit-linked policy — PHSS attaches as a rider; the customer pays for two products bundled, not one
• Customers whose base unit-linked investment value has been eroded by underperformance — biaya asuransi tambahan deducted from policy value can accelerate lapse when the policy value is already low

Do not buy PHSS — flag this to the customer if you are an Allianz / Tokio Marine agent helping them think it through

• Mass middle market (income below IDR 15M/month) — Co-Classic still requires the AIA unit-linked base; total premium load is heavy
• Customers without IDR 25M cash buffer — a single overseas hospitalisation cap blows their savings
• Customers expecting the rider to outlive a lapsed base policy — PHSS dies with the base unit-linked contract
• Customers primarily looking for a savings or investment vehicle — they need the base unit-linked discussion first, then add the rider

---

Rule of thumb for the Legacy Income agent: if a prospect says “I’m looking at AIA Saver” or “I’m comparing PHSS to your product,” do not attack PHSS. The customer has likely already accepted the co-payment principle (otherwise they would be looking at PHSE). Instead, position against the bundled-with-unit-linked structure: “PHSS works, but it’s a rider on an AIA unit-linked policy. Are you planning to take that base policy on too, or do you already have one? Because if you don’t, we can offer comparable hospital cover that doesn’t require you to start a unit-linked contract at the same time.”

---

The Indonesian health-rider / hospital-cover category in our cataloguing project has fewer than 60% of agency-only PDFs extracted to category-level quantitative benchmarks. The benchmarking below is descriptive and qualitative against the agency-channel health subset Legacy Income’s intel team has read in full; population statistics firm up once category PDF coverage exceeds 60%.

Confidence note: structural-dimension claims are high-confidence (drawn directly from brochure benefit table). Cost-of-insurance and pricing claims are inferred from brochure language (“biaya asuransi tambahan … dibebankan kepada nilai akun”) with no RIPLAY confirmation. Competitor-comparison claims are analyst assessment from category knowledge, not benchmarked against parsed competitor RIPLAYs. Refresh trigger: re-run when (a) PHSS RIPLAY becomes available, (b) health category PDF coverage exceeds 60%, or © POJK 36/2025 implementing regulations are clarified.

---

Opening — acknowledge, don’t attack

“You’ve been looking at PHSS — that’s a fair product to be considering. Before we compare features, can I ask one question: do you already have an AIA unit-linked policy, or would PHSS be your first AIA product? Because PHSS is a rider — it sits on top of an investment-linked base, and that matters for how we think about the total cost.”

“Bapak/Ibu sudah lihat PHSS — itu produk yang masuk akal untuk dipertimbangkan. Sebelum kita bandingkan fitur, boleh saya tanya satu hal: apakah Bapak/Ibu sudah punya polis unit-linked AIA, atau PHSS akan jadi produk AIA pertama? Karena PHSS itu rider — menempel di polis investasi sebagai dasar, dan itu berpengaruh ke total biaya yang harus dipikirkan.”

Reframe — the structural conversation

“The co-payment design itself is correct — POJK 36/2025 essentially requires it for any new health product issued in 2026. So whichever product you choose, you’ll have a co-payment of some kind. The questions worth asking are: what’s the cap, what’s the worldwide cover, and do I need to take a separate unit-linked policy to get this rider, or can I attach a comparable cover to a structure I already have?”

“Soal co-payment sendiri itu sudah benar — POJK 36/2025 hampir mewajibkan untuk semua produk kesehatan baru di tahun 2026. Jadi produk apapun yang Bapak/Ibu pilih, pasti ada co-payment. Pertanyaan yang sebaiknya ditanyakan: berapa cap-nya, seberapa luas cover global-nya, dan apakah saya harus ambil polis unit-linked terpisah supaya bisa pasang rider ini, atau bisa pasang cover serupa di struktur yang sudah saya punya?”

Position — without attacking

“PHSS has genuine strengths — the cap structure is clean, USA cover is rare, and the PMM service is real. The trade-off is that you’re taking on an AIA unit-linked base contract along with it. If you already wanted that base, PHSS works. If not, we have an equivalent hospital cover from Allianz or Tokio Marine that doesn’t require you to start a new unit-linked contract — same co-payment regime, similar caps, less bundling.”

“PHSS punya kelebihan nyata — struktur cap-nya bersih, cover USA jarang ada, dan layanan PMM-nya real. Trade-off-nya: Bapak/Ibu harus ambil polis unit-linked AIA sebagai dasar. Kalau memang sudah mau ambil polis dasar itu, PHSS cocok. Kalau tidak, kami ada cover rumah sakit setara dari Allianz atau Tokio Marine yang tidak mengharuskan Bapak/Ibu mulai polis unit-linked baru — co-payment-nya sama, cap-nya mirip, tapi tanpa bundling.”

Close — qualify and lead

“Let me ask the one question that actually determines which product fits: do you want your hospital cover bundled into an investment policy, or do you want it standalone? Once you tell me that, we can narrow this to two options and run a side-by-side.”

“Boleh saya tanya satu hal yang sebenarnya menentukan produk mana yang cocok: Bapak/Ibu mau cover rumah sakit yang menempel di polis investasi, atau yang berdiri sendiri? Setelah itu jelas, kita bisa kerucutkan ke dua pilihan dan bandingkan langsung.”

—

1. “Why should I share my costs? PHSE had 100% reimbursement.”

Customer “Kenapa saya harus ikut bayar? PHSE dulu 100% diganti.”

Don't say “Because the regulator forces you to.” — true but unhelpful.

Don't say “Karena regulator mewajibkan.”

Do say “POJK 36/2025 introduces a co-payment requirement for new health products in 2026 — this is industry-wide, not specific to AIA. PHSE-style 100% products will become unavailable for new business. The real question is not whether you accept co-payment — you will have to — but what kind of cap structure works for your cash position. A capped 20% with an IDR 4M ceiling per treatment in Indonesia is, in our category review, one of the more customer-friendly designs.”

Do say “POJK 36/2025 menerapkan kewajiban co-payment untuk produk kesehatan baru di 2026 — ini berlaku industri, bukan khusus AIA. Produk gaya PHSE 100% akan tidak tersedia lagi untuk bisnis baru. Jadi pertanyaan sebenarnya bukan apakah Bapak/Ibu mau co-payment — itu pasti akan ada — tapi struktur cap seperti apa yang cocok untuk arus kas. Co-pay 20% dengan plafon Rp 4 juta per perawatan di Indonesia adalah, dari review kategori kami, salah satu desain yang cukup ramah nasabah.”

—

2. “If 20% sounds small, why does it scare me on a Rp 500 juta bill?”

Customer “Kalau 20% kelihatan kecil, kenapa saya takut bayangkan tagihan Rp 500 juta?”

Don't say “20% is not 20%.” — confusing and undermines credibility.

Don't say “20% itu bukan 20% beneran.”

Do say “That’s exactly the right question. 20% without a cap on Rp 500 million is Rp 100 million — yes, scary. But PHSS caps the co-pay at Rp 4 million per treatment in Indonesia and Rp 25 million in worldwide territories. On that same Rp 500 million bill, your share in Indonesia is Rp 4 million, not Rp 100 million. The cap is what makes the product workable. Always ask any insurer ‘what’s the cap per treatment, and is it per claim or per year?’ — that’s the number that matters.”

Do say “Itu pertanyaan yang tepat sekali. 20% tanpa cap dari Rp 500 juta itu Rp 100 juta — memang menakutkan. Tapi PHSS membatasi co-pay sampai Rp 4 juta per perawatan di Indonesia dan Rp 25 juta di area dunia. Untuk tagihan Rp 500 juta tadi, bagian Bapak/Ibu di Indonesia adalah Rp 4 juta, bukan Rp 100 juta. Cap inilah yang membuat produk ini layak dipakai. Selalu tanyakan ke insurer mana pun: ‘cap-nya berapa per perawatan, dan dihitung per klaim atau per tahun?’ — itulah angka yang menentukan.”

—

3. “Are the 22% / 23% / 70% PMM outcome figures real?”

Customer “Angka 22% / 23% / 70% dari PMM itu benar tidak?”

Don't say “Yes, AIA says so.” — uncritical.

Don't say “Iya, AIA bilang begitu.”

Do say “The brochure cites Medix internal reporting from December 2023, sample of 2,500 users. The methodology and case mix are not disclosed publicly, so I would treat these as marketing-grade indicative figures, not peer-reviewed outcomes. That said — having a second-opinion service with a Singapore-based specialist is a real benefit regardless of the exact percentage. The question is whether you would actually use it. If you would, the PMM service adds value. If you would default to your current doctor, it’s a feature you’re paying for but not using.”

Do say “Brosur mengutip data internal Medix Desember 2023, sample 2.500 pengguna. Metodologi dan jenis kasusnya tidak diungkap ke publik, jadi saya akan anggap angka-angka itu sebagai indikatif marketing — bukan hasil studi yang di-review independen. Tapi — layanan second opinion dengan dokter spesialis dari Singapura itu nilai nyata, terlepas dari persentase pastinya. Pertanyaannya: apakah Bapak/Ibu betul-betul akan pakai layanan itu? Kalau iya, PMM menambah nilai. Kalau Bapak/Ibu akan tetap pakai dokter langganan, fitur ini dibayar tapi tidak terpakai.”

—

4. “What happens if my base unit-linked policy lapses?”

Customer “Kalau polis unit-linked dasar saya lapse, bagaimana?”

Don't say “It won’t lapse.” — overpromise.

Don't say “Tidak akan lapse.”

Do say “This is the most important question to ask about any unit-linked-bundled rider. PHSS premium is deducted as cost of insurance from your investment account in the base policy. If investment performance is weak and the policy value runs down, the cost of insurance still gets deducted — which accelerates the run-down. If the policy value hits zero, the rider dies with the base. Before signing, model the worst-case scenario: what happens if the investment returns 0% per year for 5 years? Ask AIA to print that illustration. If you don’t want this exposure, a standalone hospital cover with a fixed annual premium — like the Allianz or Tokio Marine equivalent — is structurally simpler.”

Do say “Ini pertanyaan paling penting untuk rider apapun yang menempel di unit-linked. Premi PHSS dipotong sebagai biaya asuransi dari saldo investasi di polis dasar. Kalau performance investasi lemah dan nilai polis menurun, biaya asuransi tetap dipotong — yang justru mempercepat penurunan. Kalau nilai polis nol, rider mati bersama polis dasar. Sebelum tanda tangan, minta proyeksi worst case: apa yang terjadi kalau return investasi 0% per tahun selama 5 tahun? Minta AIA cetak ilustrasi itu. Kalau Bapak/Ibu tidak mau menanggung risiko itu, cover rumah sakit standalone dengan premi tahunan tetap — seperti Allianz atau Tokio Marine ekuivalen — secara struktur lebih sederhana.”

—

5. “Will Halodoc telemedicine really replace doctor visits?”

Customer “Telemedicine Halodoc beneran bisa gantiin kunjungan dokter?”

Don't say “Yes, completely.” — overpromise.

Don't say “Iya, sepenuhnya.”

Do say “Halodoc telemedicine works well for follow-up consultations, prescription refills, mental-health and skin / nutrition consultations, and screening triage. It does not work for any condition requiring physical examination, imaging, or hands-on procedure. The 8 GP + 8 specialist visits per year that PHSS includes are useful as a convenience layer on top of physical visits, not as a replacement for serious in-person care. Most competitors now bundle similar telemedicine — so I’d treat this as a ‘nice to have’ rather than a decision driver between products.”

Do say “Halodoc telemedicine berfungsi baik untuk konsultasi lanjutan, isi ulang resep, konsultasi kesehatan mental, kulit dan gizi, serta triase awal. Tidak berfungsi untuk kondisi yang butuh pemeriksaan fisik, imaging, atau prosedur. 8 kunjungan dokter umum + 8 dokter spesialis per tahun di PHSS itu berguna sebagai lapisan kenyamanan di atas kunjungan fisik — bukan pengganti perawatan tatap muka serius. Kebanyakan kompetitor sekarang juga sudah bundling telemedicine serupa — jadi saya akan anggap ini fitur ‘nice to have’ bukan penentu keputusan antar produk.”

—

These are the issues most likely to trigger an OJK complaint, AAJI inquiry, or churn-back from a customer in the POJK 36/2025 regime. Build agent training around avoiding all seven.

1. Co-payment percentage without the cap. Telling a customer “the co-pay is 20%” without immediately following with “capped at IDR 4 million per treatment in Indonesia / IDR 25 million in worldwide territories” is the single highest mis-selling risk in this product. The customer will hear an unbounded 20% and either reject the product unfairly or, worse, sign without understanding the cap. Always quote percentage AND cap together — in writing on the SPAJ supplementary document.

2. Cap interpretation — per treatment, not per year. “Per Perawatan” means per treatment episode. A customer with multiple hospital admissions in one year pays the cap multiple times. The annual exposure is not capped. Walk through a hypothetical of three admissions and confirm the customer understands they could pay IDR 12 million in Indonesia or IDR 75 million worldwide in a bad year.

3. Outside-area emergency reimbursement table. Co-Classic in USA reimburses only 5% of bill. Co-Classic in Singapore reimburses 15%. Customers buying Co-Classic and then travelling for treatment will be shocked. The brochure prints the percentage table in section 23; the agent must walk the customer through their realistic travel destinations and the corresponding reimbursement column before plan selection.

4. POJK 36/2025 compliance framing. The agent should not present PHSS as “AIA’s choice” — present it as “the design that’s becoming standard across the industry in 2026.” Misrepresenting PHSS as uniquely AIA-driven creates a future complaint vector when the customer discovers every competitor has a similar product.

5. Base unit-linked policy disclosure. PHSS is a rider. The brochure states “biaya asuransi tambahan … dibebankan kepada nilai akun/hasil investasi dari produk asuransi dasar.” The customer must understand: (a) they are buying two products bundled, (b) cost of insurance deducts from investment value, © weak investment performance accelerates policy lapse, (d) if base policy lapses, rider dies. Document customer acknowledgment of all four points.

6. Personal Medical Management efficacy claims. The 22% / 23% / 70% statistics are cited to Medix internal reporting December 2023, n=2500. Methodology is not disclosed. Agents quoting these numbers as “proven outcomes” overstate the evidence base. Frame them as “AIA-published indicative figures based on their service-partner reporting,” not as independent outcome data.

7. Family Plan limit confusion. Up to 4 additional insureds with a 5% premium discount per addition. The annual limit and booster limit are still defined at the policy level and shared across all insureds — they are not multiplied by the number of insureds. A family of 5 with shared Co-Ultimate has IDR 70B lifetime shared, not IDR 350B. Walk through the shared-limit math explicitly.

---

---

1. Build a “PHSS counter-positioning” one-pager for Legacy Income agents. Page 1: acknowledge PHSS strengths (cap structure, USA cover, PMM). Page 2: position the Allianz / Tokio Marine equivalents, especially for customers who do not want the AIA unit-linked base. Include the four bundled-structure questions from Section 6.

2. POJK 36/2025 customer education sheet (EN + ID). All Legacy Income agents need to be able to explain co-payment in 90 seconds. Cover: (a) why co-payment exists in 2026, (b) the difference between capped and uncapped co-pay, © how to ask any insurer the cap question. This sheet should be product-agnostic and used at every health-insurance conversation, regardless of which product the customer ends up buying.

3. Cap-structure comparison table. Build a side-by-side of PHSS, Allianz SmartHealth (current), and Tokio Marine HS Care showing: co-pay rate, cap per treatment, cap per year (if any), and whether the rider attaches to a unit-linked base or stands alone. Refresh monthly as POJK-aligned product launches accelerate.

4. Refresh trigger 1: when AIA publishes a PHSS RIPLAY, re-pull the brochure + RIPLAY and re-run this brief against parsed RIPLAY content. Confidence will move from Medium to High.

5. Refresh trigger 2: when the Indonesia Life Insurance Market Intelligence project’s health category PDF coverage exceeds 60%, re-run the brief against quantitative category benchmarks. Until then, Section 5 is qualitative.

6. Refresh trigger 3: when POJK 36/2025 implementing regulations are published (expected Q2-Q3 2026), re-assess Section 8 compliance flags. The current flags assume the base POJK text; implementing regulations may add or modify requirements.

---